|Day Low/High||170.27 / 176.10|
|52 Wk Low/High||117.34 / 497.49|
Bear in mind that as Omicron threatens to, and will to some degree, slow economic activity, the real catalyst will be the political and policy response.
Looks like we are going to open the last day of what has been a miserable week for the markets in the red, based on where futures are currently trading. Small-caps, once again, look like they will take the brunt of the early decline. Skyworks Soluti...
* I have little conviction in this afternoon's violent rally "Nothing like price to change sentiment." - The Divine Ms. M. I read the same people you follow on Twitter. I listen to the same people you watch on Fin TV. They are emboldened (and bu...
Plus, a quick look at earnings report winners and losers from Thursday after the market closed.
Here we'll look at the iShares Genomics Immunology and Healthcare ETF and the Cancer Immunotherapy ETF to see how they stack up.
Despite the expectation of a tougher sledding for high-flying IPOs, optimism remains for a few key names.
Plus, One must ask themselves... Are Russia and China satisfied with making Ukraine and Taiwan uncomfortable? Do they understand the costs?
Whether panicked sales over these past few days, especially Wednesday, prove to be either the 'fast' or 'smart' money remains to be seen.
Sector selection will remain paramount as pandemic effects continue to permeate.
Satya Nadella's decision to sell almost half his stake in Mr. Softee prompts a closer technical look at what may lie ahead for the tech giant's shares.
The challenge for traders is determining how long the Omicron uncertainty will weigh on the markets.
* While I am not bullish, I am less bearish * On a (tactical) trading and even on an investing basis, markets may have overreacted to the Omicron news on Friday * I covered a bunch of shorts on Friday * It might be time to consider being a bit more ...
I wouldn't expect a lot in the way of economic shutdowns, at least not unless clear evidence presents that people are getting sicker from Omicron.
PFE has created what appears to potentially be the most effective antiviral for those already infected.
Plus, a thought on how the Fed could approach tapering going forward.
Small-cap biotech names are seeing dramatic, widespread declines, creating a liquidation sale for investors.
* What's to like? Very little.. * Though the averages have held up (thank you "Nifty Seven"), a look under the hood reveals a dismal picture of broken stocks and charts "Last thing I remember, I was Running for the door I had to find the passage ba...
Plus, the intersection of rising inflation and a slowing velocity of money give us reason for pause.
Let's review areas that are hot, those that are not, and how to position though January.
Knee-jerk reactions to earnings results can create attractive opportunities.
Let's see how far this pharma name could fall, even as it plays a leading role in the battle against the pandemic.
While cryptocurrencies are indeed an asset class, and they are divisible, they do not serve as a medium of exchange, and remain unproven as a store of value.
Plus, an FDA advisory panel gives a unanimous boost to a Moderna booster shot and Boeing slumps on a negative news report.
I attended the LD Micro Conference in Los Angeles. Here's what I found out.
With earnings season starting in earnest Wednesday, both indexes have offered investors nothing but lower highs coupled with lower lows since the start of September.
Market volatility could spike in late November/early December just as liquidity walks away. Keep that in mind.